We found that the conflicting activation of mitogenic ERK signaling under conditions of cell cycle arrest induces cytotoxicity in heterogenous AML cell lines following combined treatment with ATRA and CDK4/6i palbociclib. Here, MAPK1 is linked to acute myeloid leukemia.